Rare diseases
Investigational molecules
Locations
165 Chemin du Grand Revoyet, Pavillon Médical Bat 1A, Rhône, 69494 Cédex Pierre Benite, France
Centre Hospitalier Lyon Sud in Pierre Benite, France specialises in clinical trials of conditions such as Plasma cell myeloma, Non-small cell lung cancer, Acute myeloid leukaemia, Colitis ulcerative, and other specialisations. This site conducts important research.
The medical center is at the forefront of research in Cystic Fibrosis, focusing on the long-term safety and tolerability of innovative therapies. The center's work in this area aims to enhance the quality of life for patients by exploring new treatment combinations.
Through its research, the center contributes significantly to the understanding and management of Cystic Fibrosis, offering hope for improved therapeutic strategies.
Specializing in Polycythaemia Vera, the center conducts pivotal trials comparing the efficacy of ruxolitinib with other therapies. This research is crucial in preventing severe complications and improving survival rates in high-risk patients.
The center's efforts in this field are instrumental in refining treatment protocols and enhancing patient care for those with Polycythaemia Vera.
In the realm of Non-Small Cell Lung Cancer (NSCLC), the center is pioneering studies on the efficacy of combination therapies for advanced stages. This research is vital for patients with specific genetic mutations who have progressed after targeted therapies.
The center's work is pivotal in advancing treatment options and improving outcomes for patients with advanced NSCLC.
The center is a leader in exploring Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for ovarian cancer relapse. This innovative approach aims to improve survival rates and offers a promising option for patients with resectable relapses.
Through its research, the center is advancing the treatment landscape for ovarian cancer, providing new hope for patients facing relapse.
Focusing on Multiple Myeloma, the center is evaluating the efficacy of elranatamab monotherapy in patients resistant to multiple treatment lines. This research is crucial for developing new therapeutic strategies for refractory cases.
The center's contributions are vital in expanding treatment options and improving outcomes for patients with Multiple Myeloma.
The center is advancing research in the treatment of sinuses and salivary gland tumors, comparing radiotherapy with chemoradiotherapy. This study aims to optimize treatment regimens and improve progression-free survival for patients.
Through its research, the center is enhancing therapeutic approaches and patient outcomes in the treatment of these complex tumors.
In the field of Myelofibrosis, the center is evaluating the combination of pelabresib and ruxolitinib. This research is essential for improving treatment efficacy and offering new hope for patients with this challenging condition.
The center's work is crucial in advancing therapeutic options and enhancing the quality of life for patients with Myelofibrosis.
More sites in Pierre BeniteFrance
Clinical trials currently enrolling participants at this site.
A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes
FranceFranceRandomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease
FranceStudy of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis
FranceLong‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis
FranceA Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
FranceSafety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
FrancePhase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
FranceA study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer
FranceA study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.
FranceA Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis
FranceStudy of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
FranceMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
